PO.ET03.01 · 实验与分子治疗
Mechanisms of Drug Resistance 1
-
368 · PDF CDC20驱动雌激素受体阳性乳腺癌对CDK4/6抑制剂的获得性耐药 CDC20 drives acquired resistance to CDK4/6 inhibitors in estrogen receptor positive breast cancer Kamal Pandey, SM Nashir Udden, Jamsey Mathew, Prasanna G. Alluri
-
369 · PDF 利用患者来源的肺癌细胞系阐明肿瘤内异质性 Elucidation of intratumoral heterogeneity using patient-derived lung cancer cell line Tomoko Funazo, Hiroaki Ozasa, Takahiro Tsuji, Kazutaka Hosoya, Yusuke Shima, Masahiro Ooi, Keiichiro Suminaga, Kentaro Hashimoto, Hiroshi Yoshida, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Toyohiro Hirai
-
370 · PDF 低生理pH驱动P300介导的PARP1乙酰化并促进PARP抑制剂耐药 Low physiological pH drives P300 mediated acetylation of PARP1 and promotes PARP inhibitor resistance Hao Nie, Wei Zhou, Kaixin Cheng, Dajiang Guo, Liping Liao, Xu Zhang, Chen Wang, Rafal Zielinski, Janardan N. Gavade, Shruthi Sriramkumar, Yiming Fang, Shuai Wu, Hsin-Yao Tang, Andrew V. Kossenkov, Yuan Qi, Jinsong Liu, Kang Le, Dorothea C. Gruber, Michael Soth, Miriam D. Post, Anil K. Sood, Stefanie Flückiger-Mangual, Timothy A. Yap, Benjamin G. Bitler, Rugang Zhang
-
371 · PDF capivasertib介导的AKT阻断联合AR抑制在小鼠PTEN缺陷型前列腺癌中的整合分析 Integrative analysis of capivasertib mediated AKT blockade with AR inhibition in mouse PTEN-deficient prostate cancer Marco A. De Velasco, Kazuko Sakai, Daiki Nakatsu, Takafumi Minami, Mamoru Hashimoto, Shingo Toyoda, Saizo Fujimoto, Kazuhiro Yoshimura, Simon T. Barry, Cath Eberlein, Claire Rooney, Kazuto Nishio, Hirotsugu Uemura, Kazutoshi Fujita
-
372 · PDF ARNT2和AhR促进对HIF2a抑制剂belzutifan的耐药 ARNT2 and AhR promote resistance to HIF2a inhibitor belzutifan Dongkook Min, Sunil Poudel, Robert Morris, Irene Mitsiades, Monica Perez, Eric Zaniewski, Toshi Shioda, Esther Rheinbay, Mo Motamedi, Wilhelm Haas, Othon Iliopoulos
- 373 373 线粒体生物能量学维持多形性胶质母细胞瘤中ABCB1驱动的替莫唑胺耐药 Mitochondrial bioenergetics sustain ABCB1-driven temozolomide resistance in glioblastoma multiforme Ashutosh Shrivastava, Manendra Singh Tomar, Chirag Kulkarni, Sreyanko Sadhukhan, Priyanka Prajapati, Amit Lahiri, Naibedya Chattopadhyay
-
374 · PDF 靶点上的WRN突变驱动TA重复扩增的MSI癌症对WRN抑制剂的耐药 On-target WRN mutations drive resistance to WRN inhibitors in TA-repeat-expanded MSI cancers Gabriele Picco, Yanhua Rao, Angham Al Saedi, Samantha Walker, Shriram Bhosle, Yang Lee, Maria Garcia-Casado, Gilberto Valdes Garcia, Kieron May, Francesco Sassi, James P. Phelan, Philip Landis, Brian Jones, Diana Munoz, Jay Prakash Jain, Paul A. Barsanti, Joshua P. Taygerly, Michael P. DeMartino, Emanuel Gonçalves, Andrea Bertotti, Livio Trusolino, Michael A. White, Geeta Sharma, Matthew A. Coelho, Jonathan Houseley, Benjamin Schwartz, Mathew J. Garnett
-
377 · PDF 非整倍体相关的RAD21扩增对尤因肉瘤和前列腺癌中PARP抑制治疗反应的影响 Effects of aneuploidy associated RAD21 gain on therapeutic response to PARP inhibition in Ewing sarcoma and prostate cancer Chloe Springer, Elise DeArment, Ruoxi W. Wang, Thomas Janas, Xiaofeng A. Su
-
378 · PDF PGRMC1诱导的脂质代谢重编程导致肝细胞癌对索拉非尼耐药 PGRMC1 induced lipid metabolic reprogramming leads to sorafenib resistance in hepatocellular carcinoma Poornima Devi Narayanan, Abigail Ramirez, Jazmin Lopez, Mahalakshmi Vijayaraghavan, Alfredo Roman, Kyle Nguyen, Mitchel Amador Rojo, Kariina Garcia, Kritika Soni, Grace Hua, Rajkumar Lakshmanaswamy, Ramadevi Subramani
-
379 · PDF 半胱氨酸驱动的药物失活削弱共价药物疗效并驱动耐药 Cysteine-driven drug inactivation undermines covalent drug efficacy and drives resistance Maximilian Kobiesa, Jennifer A. Brain, Kelli J. Che, Leah G. Rector, Abby C. Jurasin, Sita Kugel, Lucas B. Sullivan
-
380 · PDF 染色质重连和转录可塑性驱动卵巢癌中一种独特的双重耐药状态 Chromatin rewiring and transcriptional plasticity drive a distinct dual-resistant state in ovarian cancer Won-Young Choi, Rachel Perkins, Jisun Kang, Haoxiang Lyu, Matthew S. Jung, Xiaoya Hou, Wei Li, Junming Yue, Wenjing Zhang
-
381 · PDF beta-羟基丁酸介导的赖氨酸丁酰化决定肝癌的治疗反应 beta-Hydroxybutyrate-mediated lysine butyrylation determines therapy response in liver cancer Minghe Zhang, Yunong Xie, Linglin Liu, Yimiao He, Carol Man Carol Tong
-
382 · PDF 探究LONP1在胶质母细胞瘤耐药非传统机制中的作用 Exploring the role of LONP1 in lon-traditional mechanisms of glioblastoma resistance Shashi Jain, Dahlia A. Ordaz, Javier Lepe, Naomi Lomeli, James Pham, Bhaskar Das, Daniela A. Bota
- 383 383 BRAF突变型肺腺癌中治疗持续性残留病灶的单细胞转录组分析 Single-cell transcriptomic analysis of treatment-persistent residual disease in BRAF-mutant lung adenocarcinoma Constance Nicq, Etienne Vignaud, Alice Da Silva, Raphael Schneider, Geneviève De Souza, Ludovic Bigot, Aurélie Swalduz, Olivier Calvayrac, Pierre Saintigny, Luc Friboulet, Sandra Ortiz-Cuaran
- 385 385 一种基因组来源的动态癌细胞状态非编码报告子 A genome derived non coding reporter of dynamic cancer cell state Noha Shendy, Yang Zhang, Stephanie Nance, Ha Won Lee, Shivendra Singh, Yousef Khashana, Vernon Ebegboni, Estevez Prado Daniel, Mohammad Ali Mohammad Nezhady, K. Elaine Ritter, Anoop Kavirayani, Bensheng Ju, Grace McKay-Corkum, Qi Liu, Yiping Fan, Gang Wu, Jun Qi, John B. Easton, Anand G. Patel, JUN YANG, Taosheng Chen, Brian Abraham, Adam D. Durbin
-
386 · PDF 靶向YBX1-SREBP2轴以克服肝细胞癌的药物耐药 Targeting the YBX1-SREBP2 axis to overcome drug resistance in hepatocellular carcinoma Veerababu Nagati, Yamile Abuchard Anaya, Miguel Salazar, Kaylee Renteria, Ricardo Pequeno Bracho, Manish K Tripathi
-
387 · PDF PDX药物筛选揭示结直肠癌中的精准联合治疗机会 Precision combination therapy opportunities in colorectal cancer revealed by PDX drug screening Alexey Sorokin, Preeti Kanikarla Marie, Jay Saynonh, Christian Beke Onana, Fengqin Gao, Zhensheng Liu, Maya Ridinger, Scott Kopetz
-
388 · PDF DYRK1A介导的静止状态为胶质母细胞瘤复发建立了治疗耐药性储库 DYRK1A-mediated quiescence establishes a therapeutically-resistant reservoir for glioblastoma recurrence Ameesha Paliwal, Kevin Faust, Okty Abbasi Borhani, Rifat S. Sajid, Evelyn R. Kamski-Hennekam, Ingrid Jin, Johnny L. McRae, Anzar Alvi, Parsa Babaei Zadeh, Dimitrios G. Oreopoulos, Lauren Omoto, Phedias Diamandis
-
389 · PDF GSDMB在HER2扩增型结直肠癌中驱动cGAS-STING介导的免疫逃逸 GSDMB drives cGAS-STING-mediated immune evasion in HER2-amplified colorectal cancer Junyong Weng, Tianchen Xiong, Xinxiang Li, Ajay Goel
- 390 390 单细胞多组学揭示BRCA突变型TNBC中PARP抑制剂耐药的进化和表观基因组轨迹 Single cell multiomics reveals evolutionary and epigenomic trajectories of PARP inhibitor resistance in BRCA mutant TNBC Wei Hong, Pavan Kumar, Faiza Baameur Hancock, Helen M. Piwnica-Worms, Mahinur Mattohti
-
391 · PDF TROP2和PTEN是非小细胞肺癌(NSCLC)对TUSC2基因治疗原发耐药的生物标志物 TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC) Ismail M. Meraz, Renduo Song, Shuhong Wu, Yi Xu, Meng Feng, Lihui Gao, Chenghui Ren, Qi Wang, Jun Li, Mourad Majidi, Jing Wang, Mark Berger, Jack A. Roth
-
392 · PDF EMT样重编程通过核糖体生物发生驱动套细胞淋巴瘤中耐药存留细胞的可塑性 EMT-like reprogramming drives drug-tolerant persister cell plasticity in mantle cell lymphoma via ribosome biogenesis Wei Wang, Yang Liu, Heng-Huan Lee, Fangfang Yan, Yue Fei, Yijing Li, Chengtai Yu, Lin Tan, Lorenzi Phil, Qingsong Cai, Lei Nie, Michael Wang
-
393 · PDF 通过连续肿瘤移植和全基因组CRISPR-Cas9敲除筛选揭示IDH1突变型癌症中PARP抑制剂耐药的机制 Uncovering mechanisms of PARP inhibitor resistance in IDH1-mutant cancers via serial tumor transplantation and genome wide CRISPR-Cas9 knockout screen Daniel Andres Colon-Rios, Jonathan Dow, Adam Krysztofiak, Yanfeng Liu, Faye A. Rogers, Peter M. Glazer
-
394 · PDF 肺鳞状细胞癌对mTOR抑制剂的适应性耐药机制 Adaptive resistance mechanisms to mTOR inhibitor in lung squamous cell carcinoma Milica Momcilovic
-
395 · PDF 利用全基因组CRISPR激活筛选鉴定ALK重排肺癌的耐药因子 Identification of drug resistance factors in ALK-rearranged lung cancer using genome-wide CRISPR activation screening Mai Nagasaka, Marie Kawahara, Ken Uchibori, Makoto Nishio, Ryohei Katayama
-
396 · PDF Nrf2在调控山奈酚对三阴性乳腺癌细胞中CDKs、PD-L-1、CCL2和TGM2抑制作用中的角色 Nrf2 role in regulating kaempferol's inhibitory action on CDKs, PD-L-1, CCL2, and TGM2 in triple-negative breast cancer cells Sukhmandeep Kaur, Patricia Mendonca, Shubham D. Mishra, Karam F. a. Soliman